Cochrane Review Group

Gut

172 systematic reviews in Gut ask 2,395 questions. 17.5% have no studies to answer them, 34.3% rest on very low certainty evidence and 20.6% reach moderate or high certainty.

Reviews

172

Questions

2,395

current versions

No studies

17.5%

Moderate or high

20.6%

No studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Gut

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Infliximab vs purine analogues Loss of clinical response · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Withdrawal due to adverse events · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Serious adverse events (at 2 years) · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.79 [0.37, 1.68]	1 study · 140 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Clinical relapse (at 22 weeks, CDAI > 150) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 1.01 [0.65, 1.57]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.94 [0.7, 1.25]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Withdrawal due to adverse events (at 30 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.77 [0.3, 1.97]	1 study · 53 participants	Very low
Infliximab vs placebo Loss of clinical response (at 32 weeks, less than 70 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.59 [0.37, 0.96]	1 study · 73 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Loss of clinical response (at 56 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.68 [0.29, 1.59]	1 study · 73 participants	Very low
Infliximab vs adalimumab Withdrawal due to adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.1 [0.01, 0.72]	1 study · 73 participants	Very low
Infliximab vs adalimumab Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.09 [0.01, 1.54]	1 study · 73 participants	Very low

Reviews 172

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease

Boyapati, RK, Torres, J, et al. · Cochrane Database of Systematic Reviews · 2018

Gut

Thinnest evidence

Reviews 172

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease

Cannabis for the treatment of Crohn's disease

Cannabis for the treatment of ulcerative colitis

Strategies for detecting colon cancer in patients with inflammatory bowel disease

Interventions for treating collagenous colitis

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer

Chemotherapy for advanced gastric cancer

Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults

Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children

Interventions for treating lymphocytic colitis

Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer

Proton pump inhibitors for functional dyspepsia

Pharmacological interventions for acute pancreatitis

Deprescribing versus continuation of chronic proton pump inhibitor use in adults

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy

Anti‐tuberculous therapy for maintenance of remission in Crohn's disease

Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease

Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease

Eradication therapy for peptic ulcer disease in Helicobacter pylori‐positive people

Chinese herbal medicine for oesophageal cancer

Pylorus‐preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma

Glutamine for induction of remission in Crohn's disease

Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease

Aminosalicylates for induction of remission or response in Crohn's disease